Search
Kanamycin
go.drugbank.com/drugs/DB01172ApprovedInvestigationalVet approvedWithdrawnKanamycin (also known as kanamycin A) is an aminoglycoside bacteriocidal antibiotic, available in oral, intravenous, and intramuscular forms, and used to treat a wide variety of infections.
Categories: Drugs that are Mainly Renally Excreted with a Narrow Therapeutic IndexSynonyms: Kanamycin AStreptococcus pneumoniae type 1 capsular polysaccharide antigen
go.drugbank.com/drugs/DB10319ApprovedInvestigationalIt is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia. … Streptococcus pneumoniae type 1 capsular polysaccharide antigen is a vaccine that contains highly purified capsular polysaccharides from the invasive pneumococcal type 1 of *Streptococcus pneumoniae*.
Streptococcus pneumoniae type 7f capsular polysaccharide antigen
go.drugbank.com/drugs/DB10325ApprovedInvestigationalIt is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia. … Streptococcus pneumoniae type 7f capsular polysaccharide antigen is a vaccine that contains highly purified capsular polysaccharides from the invasive pneumococcal type 7f of *Streptococcus pneumoniae*
Streptococcus pneumoniae type 9n capsular polysaccharide antigen
go.drugbank.com/drugs/DB10327ApprovedInvestigationalIt is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia. … Streptococcus pneumoniae type 9n capsular polysaccharide antigen is a vaccine that contains highly purified capsular polysaccharides from the invasive pneumococcal type 9n of *Streptococcus pneumoniae*
Streptococcus pneumoniae type 9v capsular polysaccharide antigen
go.drugbank.com/drugs/DB10328ApprovedInvestigationalIt is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia. … Streptococcus pneumoniae type 9v capsular polysaccharide antigen is a vaccine that contains highly purified capsular polysaccharides from the invasive pneumococcal type 9v of *Streptococcus pneumoniae*
Streptococcus pneumoniae type 12f capsular polysaccharide antigen
go.drugbank.com/drugs/DB10331ApprovedInvestigationalIt is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia. … Streptococcus pneumoniae type 12f capsular polysaccharide antigen is a vaccine that contains highly purified capsular polysaccharides from the invasive pneumococcal type 12f of *Streptococcus pneumoniae
Streptococcus pneumoniae type 19f capsular polysaccharide antigen
go.drugbank.com/drugs/DB10336ApprovedInvestigationalIt is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia. … Streptococcus pneumoniae type 19f capsular polysaccharide antigen is a vaccine that contains highly purified capsular polysaccharides from the invasive pneumococcal type 19f of *Streptococcus pneumoniae
Streptococcus pneumoniae type 33f capsular polysaccharide antigen
go.drugbank.com/drugs/DB10341ApprovedInvestigationalIt is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia. … Streptococcus pneumoniae type 33f capsular polysaccharide antigen is a vaccine that contains highly purified capsular polysaccharides from the invasive pneumococcal type 33f of *Streptococcus pneumoniae
Lusutrombopag
go.drugbank.com/drugs/DB13125ApprovedInvestigationalTPOR is a regulatory target site for endogenous thrombopoietin, which acts as a primary cytokine to promote megakaryocyte proliferation and differentiation, and affect other hematopoietic lineages as well … In two randomized, double-blind, placebo-controlled trials, patients with chronic liver disease and severe thrombocytopenia who were undergoing an invasive procedure with a platelet count less than 50
Grepafloxacin
go.drugbank.com/drugs/DB00365ApprovedWithdrawnGrepafloxacin is an oral broad-spectrum quinoline antibacterial agent used to treat bacterial infections. … Due to the QTc-prolonging potential, as indicated by the changes in the QT interval on the electrocardiogram, and the risk for cardiovascular adverse events, grepafloxacin was withdrawn in the United States